

64927

426

Requester's Full Name: PATEL SUDHAKER Examiner #: 77018 Date: 4/18/02
 Art Unit: 1624 Phone Number 30 84789 Serial Number: 09857995
 Mail Box and Bldg/Room Location: CIM 4E-18 Results Format Preferred (circle): PAPER DISK E-MAIL

Mail Box and Bldg/Room Location: C1114E-18 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the conception utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations (authors, etc., if known). Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: ONE OR MORE ANTINEOPLASTIC AGENTS AS A COMBINATION
THERAPY IN TREATMENT OF NEOPLASIA
Inventors (please provide full names): JOHN P. MCKEARN, JR.

Earliest Priority Filing Date: 12/25/1998

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

NEED INVENTION COMBINATION THERAPY IN TREATMENT OF
NEOPLASIA/CANCER BY USING COMPOSITION WITH
RADIATION TREATMENT.
COMPONENT A: MATRIX METALLOPROTEINASE
example

COMPONENT B:

12) NOTE CAN (COPOTECAN)

- Copy of claim 1-106 enclosed
THF
gpc
1624

POINT OF CONTACT:
PAUL SCHULWITZ
TECHNICAL INFO SPECIALIST
CM1 6806 TEL (703) 305-1954

STAFF USE ONLY

Searcher: Hau Schulwitz

Searcher Phone #:

Searcher Location: _____

Date Searcher Picked Up: 7/19

Date Completed: 4/1/77

Searcher Prep & Review Time:

Clerical Prep Time:

Online Time: _____

Type of Search

NA Sequence (#) 5

AA Sequence (#)

Structure (#) 2

Bibliographic

Litigation _____

Fulltext

Patent Family

Other _____

Vendors and cost where applicableSTN ✓ 11

Dialog

Questel/Orbit _____

Dr. Link _____

Lexis/Nexis

Sequence Systems


WWW/Internet

Other (specify) _____

=> d que

L1

STR



Component A

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 1
 CONNECT IS E2 RC AT 2
 CONNECT IS E1 RC AT 10
 CONNECT IS E1 RC AT 11
 DEFAULT MLEVEL IS ATOM
 GGCAT IS LIN LOC SAT AT 10
 GGCAT IS LIN LOC SAT AT 11
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS E4 C E1 N E1 S AT 4
 ECOUNT IS E6 C AT 6
 ECOUNT IS E5 C E1 N AT 8

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

L2 511 SEA FILE=REGISTRY ABB=ON PLU=ON NC2SC2/ES AND NC5/ES AND C6/ES


L4 9 SEA FILE=REGISTRY SUB=L2 SSS FUL L1

L5 4 SEA FILE=REGISTRY ABB=ON PLU=ON (TOPOTECAN/CN OR "TOPOTECAN HYDROCHLORIDE"/CN OR "TOPOTECAN LACTONE"/CN OR "TOPOTECAN CARBOXYLIC ACID"/CN OR TOPOTECIN/CN)

L6 3 SEA FILE=REGISTRY ABB=ON PLU=ON (IRINOTECAN/CN OR "IRINOTECAN HYDROCHLORIDE"/CN OR "IRINOTECTAN HYDROCHLORIDE HYDRATE"/CN)

L7 6 SEA FILE=REGISTRY ABB=ON PLU=ON L5 OR L6

L8 STR



Component B

or
 Topotecan
 or
 Irinotecan

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 26
 CONNECT IS E1 RC AT 27
 DEFAULT MLEVEL IS ATOM

09/857,995

April 19, 2002

GGCAT IS LIN LOC SAT AT 26
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 28


STEREO ATTRIBUTES: NONE

L10	3	SEA	FILE=REGISTRY	SSS	FUL	L8
L11	9	SEA	FILE=REGISTRY	ABB=ON	PLU=ON	L7 OR L10
L12	4	SEA	FILE=HCAPLUS	ABB=ON	PLU=ON	L4 AND L11

L12 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2002 ACS
 AN 2001:935435 HCAPLUS
 DN 136:84677
 TI Methods for enhancing antibody-induced cell lysis and treating cancer
 IN Weiner, George; Hartmann, Gunther
 PA University of Iowa Research Foundation, USA
 SO PCT Int. Appl., 312 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001097843	A2	20011227	WO 2001-US20154	20010622
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2000-213346P	P	20000622		
AB	The invention relates to methods and products for treating cancer. In particular the invention relates to combinations of nucleic acids and antibodies for the treatment and prevention of cancer. The invention also relates to diagnostic methods for screening <u>cancer cells</u> .				
IT	97682-44-5, Camptosar 100286-90-6, Campto 119413-54-6, Hycamtin 123948-87-8, Topotecan 192329-42-3, AG3340 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (immunostimulatory nucleic acids and antibody specific to CD20, CD22, CD19 or CD40 for inducing cell lysis and treating cancer)				
RN	97682-44-5	HCAPLUS	CAMPTOSAR		
CN	[1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester (9CI) (CA INDEX NAME)				


Absolute stereochemistry. Rotation (+).



RN 100286-90-6 HCAPLUS *CAMPTO*
 CN [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A




PAGE 2-A

● HCl

RN ~~119413-54-6~~ HCAPLUS *H-CAMPTIN*
 CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,

10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, monohydrochloride,
(4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 123948-87-8 HCAPLUS *TOPOTECAN*
CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,
10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (4S)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



RN 192329-42-3 HCAPLUS *A93340*
CN 3-Thiomorpholinecarboxamide, N-hydroxy-2,2-dimethyl-4-[[4-(4-
pyridinyloxy)phenyl]sulfonyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2002 ACS

AN 2000:456916 HCAPLUS

DN 133:68929

TI Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia

IN McKearn, John P.; Gordon, Gary; Cunningham, James J.; Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime L.

PA G. D. Searle & Co., USA

SO PCT Int. Appl., 358 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 9

SAME INVENTORS

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000038719	A1	20000706	WO 1999-US30700	19991222
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1140183	A1	20011010	EP 1999-968942	19991222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1998-113786P	P	19981223		
	WO 1999-US30700	W	19991222		
AB	Methods are provided to treat or prevent neoplasia disorders in a mammal using a combination of a matrix metalloproteinase inhibitor, an integrin antagonist, and an antineoplastic agent.				
IT	192329-42-3				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(AG 3340; matrix metalloproteinase inhibitor and integrin antagonist in neoplasia treatment)				
RN	192329-42-3	HCAPLUS			
CN	3-Thiomorpholinecarboxamide, N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-, (3S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



IT 97682-44-5, Irinotecan 123948-87-8, Topotecan


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(matrix metalloproteinase inhibitor and integrin antagonist in neoplasia treatment).

RN 97682-44-5 HCAPLUS

CN [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 123948-87-8 HCAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2002 ACS

AN 2000:456915 HCAPLUS

DN 133:84242

TI Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia

IN McKearn, John P.; Gordon, Gary; Cunningham, James J.; Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime L.

PA G.D. Searle & Co., USA

SO PCT Int. Appl., 277 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 9

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000038718	A2	20000706	WO 1999-US30699	19991222
WO 2000038718	A3	20001109		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1140182 A2 20011010 EP 1999-968941 19991222

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRAI US 1998-113786P P 19981223

WO 1999-US30699 W 19991222

AB Methods are provided for the prevention and treatment of neoplasia disorders in a mammal using a combination of a matrix metalloproteinase inhibitor and an antineoplastic agent.

IT 192329-42-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

Applicants


*PCT
Equiv.*

(AG 3340; matrix metalloproteinase inhibitor and antineoplastic agent as combination therapy in neoplasia treatment)

RN 192329-42-3 HCAPLUS

CN 3-Thiomorpholinecarboxamide, N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 97682-44-5, Irinotecan 123948-87-8, Topotecan


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(matrix metalloproteinase inhibitor and antineoplastic agent as combination therapy in neoplasia treatment)

RN 97682-44-5 HCAPLUS

CN [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 123948-87-8 HCAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2002 ACS

AN 2000:441655 HCAPLUS

DN 133:68922

TI Method of using a cyclooxygenase-2 inhibitor and a matrix metalloproteinase inhibitor as a combination therapy in the treatment of neoplasia

IN McKearn, John P.; Gordon, Gary; Cunningham, James J.; Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime L.

PA G.D. Searle & Co., USA

SO PCT Int. Appl., 437 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 9

INVENTORS

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000037107	A2	20000629	WO 1999-US30776	19991222
WO 2000037107	A3	20010201		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1140194	A2	20011010	EP 1999-968540	19991222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9916536	A	20020102	BR 1999-16536	19991222
NO 2001003156	A	20010823	NO 2001-3156	20010622
PRAI US 1998-113786P	P	19981223		
WO 1999-US30776	W	19991222		
AB Methods are provided to treat or prevent neoplasia disorders in a mammal using a combination of a cyclooxygenase-2 inhibitor, a matrix metalloproteinase inhibitor and an antineoplastic agent.				
IT 97682-44-5 , Irinotecan 123948-87-8 , Topotecan 192329-42-3				


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(cyclooxygenase-2 inhibitor and matrix metalloproteinase inhibitor in combination therapy for neoplasia treatment)

RN 97682-44-5 HCAPLUS

CN [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 123948-87-8 HCAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192329-42-3 HCAPLUS

CN 3-Thiomorpholinecarboxamide, N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AG 334 b